ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OBD Oxford Biodynamics Plc

9.40
-0.09 (-0.95%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biodynamics Plc LSE:OBD London Ordinary Share GB00BD5H8572 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.09 -0.95% 9.40 9.32 9.48 9.50 9.32 9.50 708,095 16:35:08
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.34M -10.83M -0.0535 -1.74 18.85M

Oxford BioDynamics PLC Appointment of Paul Stockdale as CFO (6674J)

30/06/2017 7:01am

UK Regulatory


Oxford Biodynamics (LSE:OBD)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Oxford Biodynamics Charts.

TIDMOBD

RNS Number : 6674J

Oxford BioDynamics PLC

30 June 2017

30 June 2017

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Appointment of Paul Stockdale as Chief Financial Officer

Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces the appointment of Paul Stockdale as Chief Financial Officer (CFO). Paul is expected to join the Company by 15 September 2017 and will be appointed to the Board of Directors in due course.

Paul succeeds Katie Long who is returning to her role within Tessera Investment Management Limited ("Tessera"), having established and led OBD's finance function over the previous nine months and during the Company's IPO. Katie will step down from the Board on 30 June 2017 and will support OBD on an interim basis in the transitional period.

Paul joins the Company from e-Therapeutics plc (AIM:ETX), where he has held the position of Financial Controller since January 2012. During this time he has worked closely with the CFO and has been responsible for internal and external financial reporting, and developing and maintaining financial and operational systems. Paul is a Chartered Accountant and was a Senior Manager at Deloitte, where he worked from 1996 until 2004. Following this, he worked in finance and operations management in the charitable and automotive sectors. He read Natural Sciences at St John's College, University of Cambridge.

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:

"We are delighted to welcome Paul Stockdale to the Company. Paul's extensive financial management experience, including his recent experience in another public company focused on drug discovery, will be important as OBD strides towards becoming the industry standard for epigenetic biomarker discovery.

The Board would like to take this opportunity to thank Katie for her invaluable contribution during this pivotal time for OBD. We wish her well on her return to Tessera."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Paul Leslie Stockdale, aged 42 years, has been a director of the following companies during the five years preceding the date of this announcement:

 
 Current directorships   Past Directorships 
 None                    PL & JE Services Limited 
 

The Company confirms that there is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For further details contact:

 
 Oxford BioDynamics Plc         +44 (0)1865 518910 
 Christian Hoyer Millar, 
  CEO 
 Katie Long, CFO 
 
 Stifel Nicolaus Europe 
  Limited                       +44 (0)20 7710 7600 
 Nominated Advisor and 
  Broker 
 David Arch 
 Jonathan Senior 
 Peter Lees 
 Ben Maddison 
 
 Shore Capital                  +44 (0)20 7408 4090 
 Joint Broker 
 Bidhi Bhoma 
 Edward Mansfield 
 
 FTI Consulting                 +44 (0)20 3727 1000 
 Financial Public Relations 
  Advisor 
 Julia Phillips 
 Brett Pollard 
 Natalie Garland-Collins 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue--generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOALFFIIRLIAFID

(END) Dow Jones Newswires

June 30, 2017 02:01 ET (06:01 GMT)

1 Year Oxford Biodynamics Chart

1 Year Oxford Biodynamics Chart

1 Month Oxford Biodynamics Chart

1 Month Oxford Biodynamics Chart

Your Recent History

Delayed Upgrade Clock